Exclusive Summary

• Travoprost patent expiration ensures low entry barriers and significant generic market potential.
• High global glaucoma prevalence drives continuous demand for effective and accessible treatment options.
• Travoprost is a first-line therapy, recommended by guidelines, and listed on the WHO Essential Medicines List, ensuring stable clinical status.
• Despite competition, quality-assured and cost-competitive generics can still capture substantial market share.
• International certifications and registration experience facilitate market entry and reduce BD risks for partners.